Klingenstein Fields & CO LP Amgen Inc Transaction History

Klingenstein Fields & CO LP

$2.48 Billion
Q3 2024

A detailed history of Klingenstein Fields & CO LP transactions in Amgen Inc stock. As of the latest transaction made, Klingenstein Fields & CO LP holds 1,199 shares of AMGN stock, worth $378,884. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,199

Previous 1,199 -0.0%

Holding current value

$378,884

Previous $374,000 3.21%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$262.75 - $319.31 $26,800 - $32,569	-102 Reduced 7.84%	1,199 $374,000
Q3 2023 Oct 27, 2023	BUY	$218.65 - $271.46 $24,270 - $30,132	111 Added 9.33%	1,301 $349,000
Q1 2023 Apr 28, 2023	BUY	$225.79 - $275.2 $19,869 - $24,217	88 Added 7.99%	1,190 $287,000
Q3 2022 Oct 28, 2022	SELL	$224.46 - $253.15 $10,100 - $11,391	-45 Reduced 3.92%	1,102 $248,000
Q2 2022 Aug 01, 2022	SELL	$230.71 - $256.74 $10,612 - $11,810	-46 Reduced 3.86%	1,147 $279,000
Q2 2021 Jul 26, 2021	SELL	$233.58 - $259.14 $8,642 - $9,588	-37 Reduced 3.01%	1,193 $291,000
Q1 2021 Apr 29, 2021	BUY	$221.91 - $258.6 $20,193 - $23,532	91 Added 7.99%	1,230 $306,000
Q4 2020 Feb 02, 2021	SELL	$216.38 - $257.67 $43,276 - $51,534	-200 Reduced 14.94%	1,139 $262,000
Q3 2020 Oct 30, 2020	SELL	$234.65 - $260.95 $18,302 - $20,354	-78 Reduced 5.5%	1,339 $340,000
Q2 2020 Aug 03, 2020	BUY	$197.81 - $242.74 $280,296 - $343,962	1,417 New	1,417 $334,000
Q1 2018 May 01, 2018	SELL	$169.43 - $198.0 $506,934 - $592,416	-2,992 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$167.29 - $191.0 $500,531 - $571,472	2,992	2,992 $558,000

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Klingenstein Fields & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on Klingenstein Fields & CO LP with notifications on news.

Account

Klingenstein Fields & CO LP Amgen Inc Transaction History